Optimized subunit vaccine protects against experimental leishmaniasis. Academic Article uri icon

Overview

abstract

  • Development of a protective subunit vaccine against Leishmania spp. depends on antigens and adjuvants that induce appropriate immune responses. We evaluated a second generation polyprotein antigen (Leish-110f) in different adjuvant formulations for immunogenicity and protective efficacy against Leishmania spp. challenges. Vaccine-induced protection was associated with antibody and T cell responses to Leish-110f. CD4 T cells were the source of IFN-gamma, TNF, and IL-2 double- and triple-positive populations. This study establishes the immunogenicity and protective efficacy of the improved Leish-110f subunit vaccine antigen adjuvanted with natural (MPL-SE) or synthetic (EM005) Toll-like receptor 4 agonists.

publication date

  • September 26, 2009

Research

keywords

  • Adjuvants, Immunologic
  • Antigens, Protozoan
  • Leishmaniasis Vaccines
  • Leishmaniasis, Cutaneous

Identity

PubMed Central ID

  • PMC2783536

Scopus Document Identifier

  • 70350569335

Digital Object Identifier (DOI)

  • 10.1016/j.vaccine.2009.09.066

PubMed ID

  • 19786136

Additional Document Info

volume

  • 27

issue

  • 50